These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7833096)

  • 21. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force.
    De Marinis F; Rinaldi M; Ardizzoni A; Bruzzi P; Pennucci MC; Portalone L; D'Aprile M; Ripanti P; Romano F; Belli M; Altavilla G; Migliorino MR; Rosso R; Salvati F
    Tumori; 1999; 85(3):177-82. PubMed ID: 10426128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III trial with and without lonidamine in non-small cell lung cancer.
    Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years.
    Gonzalez Baron M; Garcia Giron C; Zamora P; Garcia de Paredes ML; Feliu J; Ordoñez A; Artal A; Garrido P; Chacon JI
    Am J Clin Oncol; 1992 Feb; 15(1):23-8. PubMed ID: 1312769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.
    Veronesi A; Magri MD; Tirelli U; Carbone A; Mazza F; Franceschi S; Talamini R; Ardizzoni A; Canobbio L; Rosso R
    Am J Clin Oncol; 1988 Oct; 11(5):566-71. PubMed ID: 2845769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung: low response rate in a Cooperative Group Study. Eastern Cooperative Oncology Group.
    Vogl SE; Mehta CR; Cohen MH
    Cancer; 1979 Sep; 44(3):864-8. PubMed ID: 476598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
    Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
    J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.
    Maurer LH; Pajak T; Eaton W; Comis R; Chahinian P; Faulkner C; Silberfarb PM; Henderson E; Rege VB; Baldwin PE
    J Clin Oncol; 1985 Jul; 3(7):969-76. PubMed ID: 2991478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
    Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
    Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.
    Cellerino R; Tummarello D; Porfiri E; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1839-43. PubMed ID: 2851443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.
    James LE; Gower NH; Rudd RM; Spiro SG; Harper PG; Trask CW; Partridge M; Ruiz de Elvira MC; Souhami RL
    Br J Cancer; 1996 Jun; 73(12):1563-8. PubMed ID: 8664131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of alternating chemotherapy in patients with inoperable non-small cell lung cancer.
    Howard LM; Kasimis BS; Gramer EM; Ruddy P; Hiremath V; Pokorney ES
    Am J Clin Oncol; 1994 Feb; 17(1):83-5. PubMed ID: 8311015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non small cell lung cancer and chemotherapy.
    Nardini S
    Monaldi Arch Chest Dis; 1994 Apr; 49(2):177-8. PubMed ID: 8049706
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Therneau TM; Coles DT; Jett JR
    J Clin Oncol; 1988 Jan; 6(1):5-8. PubMed ID: 2826714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of lonidamine in non-small cell lung cancer: final report.
    Kokron O; Maca S; De Gregorio M; Ciottoli GB
    Br J Cancer; 1990 Feb; 61(2):316-8. PubMed ID: 2155644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.